The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
Recent research has led to a new treatment regimen that will affect millions of multiple sclerosis patients around the world. The U.S. Food and Drug Administration has approved a new drug application ...
Teva ($TEVA) doesn't have much time left to switch patients over to its new, thrice-weekly Copaxone injection before generics jump on the current product. And while ...
<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
COPAXONE (glatiramer acetate) Injection 40mg/mL Teva announced the FDA approval of Copaxone (glatiramer acetate injection) 40mg/mL, a new strength of Copaxone injection. Teva announced the FDA ...
COPAXONE (glatiramer acetate) Injection 40mg/mL Teva announced new data on the safety and efficacy of Copaxone (glatiramer acetate injection) 40mg/mL in patients with relapsing forms of multiple ...
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent ...
Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback